3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1/2
1
Status
Active not recruiting
2
Recruiting
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
Breast
18
Gastrointestinal
12
Gynecologic
6
Tumor-Agnostic
4
Thoracic
3
Sarcoma
3
CNS
3
Head & Neck
2
Genitourinary
2
Dermatologic
1
Conditions
Breast Neoplasms
3
Brain Neoplasms
2
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Glioma
1
Fallopian Tube Neoplasms
1
Astrocytoma
1
Interventions
Temozolomide
43
Magnetic Resonance Spectroscopy
39
Specimen Handling
29
Radiotherapy
19
Radiation
16
Bevacizumab
14
Biopsy
13
Nivolumab
12
Radiosurgery
11
X-Rays
9
Cyclophosphamide
9
Carboplatin
8
Nuclear Medicine Department, Hospital
7
Irinotecan
7
Ipilimumab
6
Cisplatin
6
AZD 6244
6
Vincristine
5
Topotecan
5
Phantoms, Imaging
5
Lomustine
5
Etoposide
5
CTLA-4 Antigen
5
ulixertinib
4
trametinib
4
pembrolizumab
4
olaparib
4
erdafitinib
4
dinutuximab
4
Surveys and Questionnaires
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
trastuzumab deruxtecan
×
CNS
×
30 days
×
Clear all
NCT05417594
2026-06-02
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled
NCT04739761
2026-05-12
DESTINY-B12
AstraZeneca
Phase 3
Active not recruiting
506 enrolled
27 charts
NCT06048718
2026-05-08
TUXEDO-4
MedSIR
Phase 2
Active not recruiting
28 enrolled